| ID | 1057 |
| Name of the vaccine | Pediacel |
| Microbe | Bacteria |
| Disease name | Pertussis (Whooping Cough) |
| Name of bacteria | Bordetella pertussis |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | Over 6 weeks |
| Description of the vaccine | Diphtheria, tetanus toxoids, acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine and haemophilus b conjugate vaccine
(Tetanus protein conjugate). |
| Name of the manufacturer | Sanofi Pasteur Limited |
| Name of the manufacturing country | Canada |
| Year of manufacture | 2004 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative coccobacillus. |
| Efficacy | Seroconversion/seroresponse rates against PT, FHA, and PRN antigens were 91.3%, 78.7%, and 83.0–97.8%. |
| Vaccine formulation | White to off-white suspension for injection |
| Dosage | Primary vaccination: Two or three dose series, gap of at least 1 month.
Booster vaccination: Single dose, 6 months after the last dose. |
| Mechanism of action | Not clearly defined. |
| Route of administration | Intramuscular |
| Indications | Immunization against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b disease. |
| Export | EU marketing authorisation |
| Approval | NA |
| Adjuvant | Aluminium phosphate |
| Repurposing | For diphtheria, tetanus, pertussis, poliomyelitis and Hib. |
| Side effects of vaccine | Redness, swelling or tenderness, irritability, less activity, vomiting, unusual high-pitched crying, fever, appetite loss, diarrhoea. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | 21999652 |
| Clinical trial number | NA |
| Reference | NA |
| Other name | NA |
| Additional Links | https://pdf.hres.ca/dpd_pm/00015723.PDF
|